U. ROCHESTER (US) — The most common type of malignant brain tumor gets its start in cells known as glial progenitor cells—often referred to as “daughter” cells of stem cells.
Details of the research are reported in the journal Cancer Cell.
The work comes at a time when researchers are actively investigating the role that stem cells which have gone awry play in causing cancer.
For scientists trying to create new ways to treat brain tumors, knowing whether stem cells or progenitor cells are part of the process is crucial.
“In many ways progenitor cells are controlled by completely different signaling pathways than true stem cells,” says Steven Goldman, director of neurology at the University of Rochester.
“Knowing which type of cell is involved gives us a clear look at what drug approaches might be useful to try to stop these tumors. Comparing normal progenitor cells to progenitors that give rise to tumors gives us a roadmap to follow as we try to develop new treatments.”
The study focuses on oligodendrogliomas, a type of tumor that presents with symptoms much like other brain tumors—headaches, seizures, and cognitive changes that are treated with a combination of surgery, radiation, and chemotherapy.
Oligodendrogliomas at first are less deadly and invasive than most other gliomas. Unfortunately, treatments like surgery typically slow or stop the tumor initially, but it usually returns, often in a much more aggressive form than it was to begin with.
The majority of patients with oligodendrogliomas ultimately die from the disease.
In order to identify better treatments for this tumor, researchers need to know what cell type in the brain gives rise to it.
Scientists used a common brain tumor drug, temozolomide, to test several types of cells from both human and mouse tumors and found that the drug was effective against oligodendroglioma cells and normal glial progenitor cells, and much less effective against either brain stem cells or other brain tumors called astrocytomas.
The work is the latest in a string of findings that progenitor cells are the origin for some brain tumors.
Four years ago, Goldman’s team pinpointed a progenitor cell as the origin of a brain tumor known as a neurocytoma. Separately, other scientists have found that brain tumors called medulloblastomas and ependymomas also arise from progenitor cells.
“Right now, when treating most brain tumor patients, one size fits all,” Goldman says. “As with many forms of cancer, today’s treatments of glioma are not very specific—they take aim at all dividing cells.
Unfortunately, with brain tumors, it’s often the most aggressive, malignant cells that survive chemotherapy and radiation, and they take over the tumor and ultimately kill the patient.
“As with any type of cancer, the hope ultimately is to create treatments that target cancer cells while leaving healthy cells intact. That’s where our current work—searching for differences between normal progenitor cells and cancer progenitor cells—fits in.”
Rochester’s portion of the study, part of a multi-institutional collaboration led by William Weiss, a neuro-oncologist at the University of California at San Francisco, was supported by the New York State Stem Cell Science Board, the Adelson Medical Research Foundation, and the James S. McDonnell Foundation.
Researchers from the University at Buffalo and the University of Connecticut contributed to the study.
More news from University of Rochester: www.rochester.edu/news